In this video, acute myeloid leukemia (AML) expert Dr. Barry Skikne discusses leading clinical trials for older patients with AML and some of their outcomes. In an AML maintenance study, the HOVON trial using hypomethylating agents was designed to measure overall survival and relapse-free survival in elderly patients who had previous intensive chemotherapy. The study's importance is discussed comparing both relapse-free survival to disease-free survival in AML patients with findings suggesting benefits in relapse-free survival but not overall survival benefits. In a recent Oral Azacitidine Study in AML patients who continued on to maintenance therapy, significant improvement in overall survival and relapse-free survival was established. Moreover, oral azacitidine was found to be well tolerated with acceptable safety in clinical trial patients.  Other studies are evaluating combination therapies to improve AML patient outcomes and it is important for patients to discuss clinical trials with their providers.

• Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.